These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 28979335)

  • 61. Dynamics of coexisting HCMV-UL97 and UL54 drug-resistance associated mutations in patients after haematopoietic cell transplantation.
    Göhring K; Wolf D; Bethge W; Mikeler E; Faul C; Vogel W; Vöhringer MC; Jahn G; Hamprecht K
    J Clin Virol; 2013 May; 57(1):43-9. PubMed ID: 23375740
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.
    Chon WJ; Kadambi PV; Xu C; Becker YT; Witkowski P; Pursell K; Kane B; Josephson MA
    Case Rep Nephrol Dial; 2015; 5(1):96-105. PubMed ID: 26000278
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.
    Chou S; Erice A; Jordan MC; Vercellotti GM; Michels KR; Talarico CL; Stanat SC; Biron KK
    J Infect Dis; 1995 Mar; 171(3):576-83. PubMed ID: 7876604
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Detection of ganciclovir resistance mutations quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease.
    Boivin G; Chou S; Quirk MR; Erice A; Jordan MC
    J Infect Dis; 1996 Mar; 173(3):523-8. PubMed ID: 8627012
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE; Knudsen JL; Lease ED; Jerome KR; Rakita RM; Boeckh M; Limaye AP
    Clin Infect Dis; 2017 Jul; 65(1):57-63. PubMed ID: 28369203
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
    Li F; Kenyon KW; Kirby KA; Fishbein DP; Boeckh M; Limaye AP
    Clin Infect Dis; 2007 Aug; 45(4):439-47. PubMed ID: 17638191
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.
    Boivin G; Gilbert C; Gaudreau A; Greenfield I; Sudlow R; Roberts NA
    J Infect Dis; 2001 Dec; 184(12):1598-602. PubMed ID: 11740736
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis.
    Liu W; Kuppermann BD; Martin DF; Wolitz RA; Margolis TP
    J Infect Dis; 1998 May; 177(5):1176-81. PubMed ID: 9593000
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Study of cytomegalovirus resistance in allogeneic hematopoietic cell transplant recipients.
    Guiu A; López-Aladid R; Cardeñoso L; Mosquera MM; de la Cámara R; Marcos MA
    Med Clin (Barc); 2020 Jun; 154(11):433-439. PubMed ID: 31785805
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
    Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
    J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
    [TBL] [Abstract][Full Text] [Related]  

  • 72. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
    Smith IL; Cherrington JM; Jiles RE; Fuller MD; Freeman WR; Spector SA
    J Infect Dis; 1997 Jul; 176(1):69-77. PubMed ID: 9207351
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.
    Boutolleau D; Burrel S; Agut H
    Antiviral Res; 2011 Jul; 91(1):32-5. PubMed ID: 21570426
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.
    Erice A; Gil-Roda C; Pérez JL; Balfour HH; Sannerud KJ; Hanson MN; Boivin G; Chou S
    J Infect Dis; 1997 May; 175(5):1087-92. PubMed ID: 9129070
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
    Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genotypic resistance of cytomegalovirus to antivirals in hematopoietic stem cell transplant recipients from Portugal: A retrospective study.
    Campos AB; Ribeiro J; Pinho Vaz C; Campilho F; Branca R; Campos A; Baldaque I; Medeiros R; Boutolleau D; Sousa H
    Antiviral Res; 2017 Feb; 138():86-92. PubMed ID: 27887982
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Contribution of next generation sequencing to early detection of cytomegalovirus UL97 emerging mutants and viral subpopulations analysis in kidney transplant recipients.
    Garrigue I; Moulinas R; Recordon-Pinson P; Delacour ML; Essig M; Kaminski H; Rerolle JP; Merville P; Fleury H; Alain S
    J Clin Virol; 2016 Jul; 80():74-81. PubMed ID: 27214758
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
    McGavin JK; Goa KL
    Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Persistent primary cytomegalovirus infection in a kidney transplant recipient: Multi-drug resistant and compartmentalized infection leading to graft loss.
    Andrei G; Van Loon E; Lerut E; Victoor J; Meijers B; Bammens B; Sprangers B; Gillemot S; Fiten P; Opdenakker G; Lagrou K; Kuypers D; Snoeck R; Naesens M
    Antiviral Res; 2019 Aug; 168():203-209. PubMed ID: 31212020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.